» Articles » PMID: 39422551

A View of Myeloid Transformation Through the Hallmarks of Cancer

Overview
Specialties Hematology
Oncology
Date 2024 Oct 18
PMID 39422551
Authors
Affiliations
Soon will be listed here.
Abstract

The development of myeloid malignancies is influenced by a range of cell-intrinsic and cell-extrinsic factors, which can be conceptualized using the hallmarks of cancer. Although many facets of myeloid transformation are similar to those in solid tumors, there are also notable differences. Unlike solid tumors, hematologic malignancies typically exhibit fewer genetic mutations, which have been well characterized. However, understanding the cell-extrinsic factors contributing to myeloid malignancies can be challenging due to the complex interactions in the hematopoietic microenvironment. Researchers need to focus on these intricate factors to prevent the early onset of myeloid transformation and develop appropriate interventions. Significance: Myeloid malignancies are common in the elderly, and acute myeloid leukemia has an adverse prognosis in older patients. Investigating cell-extrinsic factors influencing myeloid malignancies is crucial to developing approaches for preventing or halting disease progression and predicting clinical outcomes in patients with advanced disease. Whereas successful intervention may require targeting various mechanisms, understanding the contribution of each cell-extrinsic factor will help prioritize clinical targets.

References
1.
Trowbridge J, Starczynowski D . Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J Exp Med. 2021; 218(7). PMC: 8210621. DOI: 10.1084/jem.20201544. View

2.
Marlein C, Zaitseva L, Piddock R, Robinson S, Edwards D, Shafat M . NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. Blood. 2017; 130(14):1649-1660. DOI: 10.1182/blood-2017-03-772939. View

3.
Allen P, Lu X, Chen Q, OShea K, Chmiel J, Slonim L . Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv. 2022; 7(12):2670-2676. PMC: 10333742. DOI: 10.1182/bloodadvances.2022008116. View

4.
Grockowiak E, Korn C, Rak J, Lysenko V, Hallou A, Panvini F . Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms. Nat Cancer. 2023; 4(8):1193-1209. PMC: 10447237. DOI: 10.1038/s43018-023-00607-x. View

5.
Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman F, Lee T . Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer Discov. 2021; 11(6):1542-1561. PMC: 8178167. DOI: 10.1158/2159-8290.CD-20-1375. View